Donnelly D, Preshlock S, Kaur T, Tran T, Wilson T, Mhanna K
Front Nucl Med. 2024; 1:820235.
PMID: 39355640
PMC: 11440948.
DOI: 10.3389/fnume.2021.820235.
Terracina S, Ferraguti G, Tarani L, Fanfarillo F, Tirassa P, Ralli M
Curr Issues Mol Biol. 2023; 45(11):8950-8973.
PMID: 37998739
PMC: 10670231.
DOI: 10.3390/cimb45110562.
Park H, Chae M, Ko J, Kikkawa D, Jang S, Yoon J
PLoS One. 2022; 17(12):e0279060.
PMID: 36521376
PMC: 9754806.
DOI: 10.1371/journal.pone.0279060.
Carnero Contentti E, Correale J
Drug Des Devel Ther. 2022; 16:3473-3490.
PMID: 36238195
PMC: 9553159.
DOI: 10.2147/DDDT.S348129.
Kokabee M, Wang X, Voorand E, Alin E, Kokabee L, Khan F
Cancer Genomics Proteomics. 2022; 19(4):415-427.
PMID: 35732327
PMC: 9247882.
DOI: 10.21873/cgp.20329.
The Multifaceted Roles of Mast Cells in Immune Homeostasis, Infections and Cancers.
Sobiepanek A, Kuryk L, Garofalo M, Kumar S, Baran J, Musolf P
Int J Mol Sci. 2022; 23(4).
PMID: 35216365
PMC: 8875910.
DOI: 10.3390/ijms23042249.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
Esfandiari E, Chen M, Smithson G, Blair D, Faessel H, Wagner J
Clin Transl Sci. 2021; 14(3):820-828.
PMID: 33650758
PMC: 8212709.
DOI: 10.1111/cts.12871.
Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.
Yu H, Truong H, Mitchell S, Liclican A, Gosink J, Li W
SLAS Discov. 2018; 23(9):919-929.
PMID: 30011241
PMC: 6151956.
DOI: 10.1177/2472555218786165.
BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling.
Gu C, Peng H, Lu Y, Yang H, Tian Z, Yin G
Oncotarget. 2017; 8(34):56858-56867.
PMID: 28915637
PMC: 5593608.
DOI: 10.18632/oncotarget.18096.
Dynamics of the Tec-family tyrosine kinase SH3 domains.
Roberts J, Tarafdar S, Joseph R, Andreotti A, Smithgall T, Engen J
Protein Sci. 2016; 25(4):852-64.
PMID: 26808198
PMC: 4941224.
DOI: 10.1002/pro.2887.
Silencing Bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS/immune complex-induced acute lung injury.
Krupa A, Fol M, Rahman M, Stokes K, Florence J, Leskov I
Am J Physiol Lung Cell Mol Physiol. 2014; 307(6):L435-48.
PMID: 25085625
PMC: 4166786.
DOI: 10.1152/ajplung.00234.2013.
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.
Akinleye A, Avvaru P, Furqan M, Song Y, Liu D
J Hematol Oncol. 2013; 6(1):88.
PMID: 24261963
PMC: 3843585.
DOI: 10.1186/1756-8722-6-88.
Ibrutinib and novel BTK inhibitors in clinical development.
Akinleye A, Chen Y, Mukhi N, Song Y, Liu D
J Hematol Oncol. 2013; 6:59.
PMID: 23958373
PMC: 3751776.
DOI: 10.1186/1756-8722-6-59.
Bruton's tyrosine kinase mediates FcγRIIa/Toll-like receptor-4 receptor crosstalk in human neutrophils.
Krupa A, Fudala R, Florence J, Tucker T, Allen T, Standiford T
Am J Respir Cell Mol Biol. 2012; 48(2):240-9.
PMID: 23239500
PMC: 3604059.
DOI: 10.1165/rcmb.2012-0039OC.
Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.
Balakrishnan K, Gandhi V
Expert Opin Investig Drugs. 2012; 21(4):409-23.
PMID: 22409342
PMC: 4142764.
DOI: 10.1517/13543784.2012.668526.
Mutation of tyrosine 145 of lymphocyte cytosolic protein 2 protects mice from anaphylaxis and arthritis.
Lenox L, Kambayashi T, Okumura M, Prieto C, Sauer K, Bunte R
J Allergy Clin Immunol. 2009; 124(5):1088-98.
PMID: 19895996
PMC: 2778804.
DOI: 10.1016/j.jaci.2009.08.038.
Tec kinases regulate actin assembly and cytokine expression in LPS-stimulated human neutrophils via JNK activation.
Zemans R, Arndt P
Cell Immunol. 2009; 258(1):90-7.
PMID: 19393603
PMC: 2697619.
DOI: 10.1016/j.cellimm.2009.03.017.
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles F
Target Oncol. 2009; 4(2):99-105.
PMID: 19381453
DOI: 10.1007/s11523-009-0110-4.
The tyrosine kinase network regulating mast cell activation.
Gilfillan A, Rivera J
Immunol Rev. 2009; 228(1):149-69.
PMID: 19290926
PMC: 2669301.
DOI: 10.1111/j.1600-065X.2008.00742.x.
The Tec family kinase, IL-2-inducible T cell kinase, differentially controls mast cell responses.
Iyer A, August A
J Immunol. 2008; 180(12):7869-77.
PMID: 18523250
PMC: 2583454.
DOI: 10.4049/jimmunol.180.12.7869.